Attainable predictive biomarkers for tumor response to mTOR inhibitors, as are actually described in glioblastoma, breast and prostate cancer cells, would be the differential expression of mTOR pathway proteins, PTEN, AKT, and S6.[one] Thus, this data relies on preclinical assays, based upon in vitro cultured tumor cell strains, which recommend tha